A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
Exploratory Study of the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
Mayo Clinic
30 participants
Mar 3, 2023
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.
Eligibility
Inclusion Criteria3
- Individuals on an unrestricted regular diet with no dietary restrictions (vegan, low FODMAP, gluten free, dairy-free etc) or other fad diets (e.g., keto, intermittent fasting, etc.).
- Healthy subjects will be screened for current or chronic GI symptoms using a 16-item questionnaire.
- Only those with an absence of symptoms will eligible to participate.
Exclusion Criteria4
- For healthy volunteers, will include prior surgery altering the esophagus, stomach, and intestine (except appendectomy).
- Chronic daily use of medications affecting GI secretion or motor function.
- The presence of any GI-motility affecting systemic diseases or untreated psychiatric disease.
- Pregnancy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
40 MG oral capsules daily
Given as Culturelle Digestive Probiotic in the form of oral capsules daily
Oral capsules daily that look exactly like the study drug, but contains to active ingredient
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05517928